Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06637527 · ClinicalTrials.gov registry record · Phase 2
The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
A Phase 2 study, sponsored by Okyo Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT06637527 is a Phase 2 study that was terminated before completion, run by Okyo Pharma. The registered enrollment target is 18 participants.
The verdict
NCT06637527, a Phase 2 study, was terminated before completion, sponsored by Okyo Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective of this study, in subjects with Neuropathic Corneal Pain, is to evaluate the efficacy and safety of OK-101 0.05% and 0.1% as compared to placebo instilled 4 times/day in subjects with neuropathic corneal pain, as assessed by visual analogue scale (VAS).
Interventions
- DRUG Placebo
- DRUG OK-101 0.05%
- DRUG OK-101 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06637527
The ClinicalTrials.gov registry entry for NCT06637527 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Okyo Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06637527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06637527 about?
NCT06637527 is a clinical study titled "The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain". The primary objective of this study, in subjects with Neuropathic Corneal Pain, is to evaluate the efficacy and safety of OK-101 0.05% and 0.1% as compared to placebo instilled 4 times/day in subjects with neuropathic corneal pain, as assessed by visual analogue scale (VAS).
What is the current status of trial NCT06637527?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2024-10-15. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT06637527?
The interventions under investigation include: Placebo (DRUG), OK-101 0.05% (DRUG), OK-101 0.1% (DRUG).
Who is sponsoring clinical trial NCT06637527?
This trial is sponsored by Okyo Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.